Clinical Trial Update: A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial assessed PF-00868554 in combination with Pegasys and Copegus for chronic hepatitis C genotype 1; results from the completed study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• PF-00868554
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Pfizer | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2013-08-26